Healthcare Industry News: thrombosis
News Release - June 1, 2011
GORE(R) Hybrid Vascular Graft Commercially Available in the United StatesOptimal Outflow with Expanded Treatment Options for Dialysis Access Patients, More than 130 Successful Implants
FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)-- W. L. Gore & Associates (Gore) today is announcing commercial availability in the US of the GORE® Hybrid Vascular Graft. The Gore device expands treatment options and improves blood flow for dialysis access patients with end-stage renal disease (ESRD). More than 130 dialysis access patients have been successfully treated with the GORE Hybrid Vascular Graft. Three month follow-up data for newly created access implants demonstrates a trend toward a reduction in revision procedures, thrombosis events and seroma, as compared to historical graft data. In the United States, more than 300,000 people suffer from ESRD and are in need of dialysis.
The GORE Hybrid Vascular Graft is indicated for use as a vascular prosthesis for dialysis access or bypass for other peripheral vascular diseases. The device is designed to address the most common causes of graft failure; intimal hyperplasia, thrombosis, and seroma. The device simplifies access to vessels with a new over the wire deployment method through a smaller than usual incision in the skin that reduces vessel injury and dissection. The GORE Hybrid Vascular Graft has been used to create new access sites in anatomical locations that would have been abandoned otherwise, preserving the amount of access sites available throughout the patient’s long-term therapy.
Since receiving FDA clearance in 2010, more than 130 patients were treated with the GORE Hybrid Device at multiple centers across the US. John R. Ross, MD, General Surgeon at the Bamberg County Hospital, Bamberg, South Carolina performed the first clinical implants.
“Outflow stenosis has been a long-standing challenge for vascular grafts. The GORE Hybrid Vascular Graft is a promising new option because it targets intimal hyperplasia by creating a sutureless anastomosis that can be created percutaneously,” said Dr. Ross. “This new device directs the outflow so it is in-line with the vessel and shields the area most prone to intimal hyperplasia and failure.”
The GORE Hybrid Vascular Graft combines several trusted Gore technologies. The expanded polytetrafluoroethylene (ePTFE) vascular prosthesis has a section reinforced with nitinol. The nitinol reinforced section is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations. It is the only combination graft that incorporates Carmeda® BioActive Surface (CBAS® Surface) end-point immobilization of heparin to the luminal surface, resulting in a proven thromboresistant surface.
“We are very excited to introduce the GORE Hybrid Vascular Graft that has the potential to significantly improve outcomes,” said Chuck Biggerstaff, associate with the Gore Venous Access Business. “This device is the latest addition to Gore’s long history of introducing innovative devices and technologies to positively impact the lives of patients worldwide.”
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for three decades. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 14th consecutive year. For more information, visit www.goremedical.com.
Products listed may not be available in all markets. GORE® and designs are trademarks of W. L. Gore & Associates. CARMEDA® and CBAS® are trademarks of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.
Source: W. L. Gore
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.